Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg
Status:
Terminated
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
Irritable bowel syndrome is a complex condition with a high unmet medical need for effective
and safe treatment options. Lacteol® is a lactobacillus product used for adjunctive and
symptomatic treatment of diarrhea. In this study, Lacteol® 340 mg will be evaluated as a
potential therapy for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).